Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft

Prostate

Volumn 70, Issue 3, 2010, Pages 252-261

  Terada, Naoki ^a   Shimizu, Yosuke ^a   Yoshida, Toru ^b   Maeno, Atsushi ^a   Kamba, Tomomi ^a   Inoue, Takahiro ^a   Nakamura, Eijiro ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Androgen receptor mutation; Bicalutamide; Flutamide; Novel experimental model; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CYSTEINE; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; HUMANS; MALE; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETREATMENT; SUBSTANCE WITHDRAWAL SYNDROME; TOSYL COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TRYPTOPHAN;

EID: 75649125314     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21058     Document Type: Article

References (42)

1. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967;27(11):1925-1930.
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491-1498.
3. Scher HI, KellyWK.Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11(8):1566-1572.
4. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004;171(2 Pt 1):679-683.
5. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005; 96(6):791-795.
6. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175(1):27-34.
7. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007;14(2):128-132.
8. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int J Urol 2007;14(3):264-267.
9. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180(3):921-927.
10. Veldscholte J, Ris-StalpersC, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor ofhumanLNCaPcells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-540.
11. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997;3(8):1383-1388.
12. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6(6):703-706.
13. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21(14):2673-2678.
14. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65(21):9611-9616.
15. Nakao R, Haji M, Yanase T, Ogo A, Takayanagi R, Katsube T, Fukumaki Y, Nawata H. A single amino acid substitution (Met786 - Val) in the steroid-binding domain of human androgen receptor leads to complete androgen insensitivity syndrome. J Clin Endocrinol Metab 1992;74(5):1152-1157.
16. Segawa T, Takebayashi H, Kakehi Y, Yoshida O, Narumiya S, Kakizuka A. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy. Cancer Res 1998;58(11):2282-2287.
17. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66(2):332-337.
18. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 1995;16(3):271-321.
19. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69(1-6): 307-313.
20. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
21. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer.N Engl J Med 2003;349(4):366-381.
22. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52(6):1598-1605.
23. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G. The human PC346 xenograft and cell line panel:Amodel system for prostate cancer progression. Eur Urol 2006;49(2):245-257.
24. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20(1):22-45.
25. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997;75(2):190-195.
26. Agoulnik IU, Weigel NL. Androgen receptor action in hormonedependent and recurrent prostate cancer. J Cell Biochem 2006; 99(2):362-372.
27. Pilat MJ, Kamradt JM, Pienta KJ. Hormone resistance in prostate cancer. Cancer Metastasis Rev 1998;17(4):373-381.
28. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm 1994; 49:383-432.
29. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7(12):1541-1550.
30. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-1398.
31. Duff J, McEwan IJ. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol 2005;19(12):2943-2954.
32. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11):2511-2515.
33. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP. Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004;108(1):152-157.
34. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
35. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ, Koivisto PA. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001;81(12):1647-1651.
36. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor:Apossible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63(1):149-153.
37. Marhefka CA, MooreBMII, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT, Miller DD. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. JMed Chem 2001;44(11): 1729-1740.
38. Bohl CE, Chang C, Mohler ML, Chen J, Miller DD, Swaan PW, Dalton JT. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. JMed Chem 2004;47(15):3765-3776.
39. Soderholm AA, Lehtovuori PT, Nyronen TH. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. JMed Chem 2005;48(4):917-925.
40. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR Jr, Weinmann R, Einspahr HM. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad SciUSA 2001;98(9):4904-4909.
41. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005;102(17):6201-6206.
42. Inoue T, Kobayashi T, Terada N, Shimizu Y,KamotoT,OgawaO, NakamuraE. The role of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Rev Endcrinol Metab 2007;2(5): 1-16.